Pharmaust Limited (ASX:PAA)

9.8¢

right-arrow Created with Sketch. 0.001 (1.03%)
MCAP $31.05M
Last trade 15.44pm 26/11/2021 20mins delayed

Latest Announcements

17/11/2021 Price SensitivePSPAAPharmaust Limited
16/11/2021PAAPharmaust Limited
264
MCap
16/11/2021PAAPharmaust Limited
15/11/2021 Price SensitivePSPAAPharmaust Limited
12/11/2021PAAPharmaust Limited
09/11/2021PAAPharmaust Limited
09/11/2021PAAPharmaust Limited
09/11/2021PAAPharmaust Limited

Company Overview

Pharmaust Limited is an Australia-based clinical-stage pharmaceutical company. The Company is focused on developing therapeutics for cancer, neurodegenerative diseases and viral infections in humans and cancer for pet dogs. The Company's lead candidate, monepantel (MPL), is a small molecule drug primarily being developed as a safe and potent treatment for cancer. The MPL can also be used for neurodegenerative diseases such as Motor Neuron Disease, Parkinson's Disease, and Alzheimer's Disease. It has completed Phase I clinical trials with MPL in humans and dogs diagnosed with solid tumors. The Company has also initiated a preclinical program to screen its portfolio of aminoacetonitrile (AAD) compounds for anticancer activity.

PAA in the news

PharmAust (PAA) sets a start date for its clinical trials for its…
PharmAust (PAA) signs agreements to expand its canine lymphoma studies into New…
PharmAust (PAA) has reached out to COVID-19 trial sites following production of…
Clinical-stage biotech company PharmAust (PAA) identifies the optimum monepantel (MPL) drug plasma…

Search Previous Announcements